Meropenem (English Wikipedia)

Nadeem I, Ingle T, Ur Rasool M, Mahdi N, Ul Munamm SA, Rabiei B, et al. (2023). "P114 Nebulised meropenem for prevention of bronchiectasis exacerbation". 'It's not easy being green' – Suppurative lung diseases. Vol. 78. pp. A175.1–A175. doi:10.1136/thorax-2023-BTSabstracts.266. Archived from the original on February 21, 2024. Retrieved February 21, 2024.

books.google.com (Global: 3^rd place; English: 3^rd place)

Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 497. ISBN 978-3-527-60749-5. Archived from the original on February 27, 2024. Retrieved September 20, 2020.

compendium.com.ua (Global: low place; English: low place)

"Меропенем (Meropenemum)". compendium.com.ua (in Ukrainian). Compendium. Archived from the original on May 20, 2022. Retrieved May 21, 2022.

doi.org (Global: 2^nd place; English: 2^nd place)

Mohr Iii JF (2008). "Update on the Efficacy and Tolerability of Meropenem in the Treatment of Serious Bacterial Infections". Clinical Infectious Diseases. 47: S41–S51. doi:10.1086/590065. PMID 18713049.
Michelow IC, McCracken GH (2009). "Antibacterial Therapeutic Agents". Feigin and Cherry's Textbook of Pediatric Infectious Diseases. pp. 3178–3227. doi:10.1016/B978-1-4160-4044-6.50253-3. ISBN 978-1-4160-4044-6. As with other β-lactam antibiotics, meropenem is bactericidal against susceptible bacteria because it inhibits bacterial cell wall synthesis. The trans configuration of the hydroxyethyl side chain and hydrogen atoms protect the parent β-lactam structure from inactivation by the most common β-lactamases, including almost all Bush groups 1 and 2 (Amber classes A, C, and D) β-lactamase–producing organisms, including those that produce ESBLs (Citrobacter, Enterobacter, E. coli, Klebsiella spp., and P. mirabilis) or AmpC β-lactamases (Citrobacter, Enterobacter, Pseudomonas, and Serratia)
Ikenoue C, Matsui M, Inamine Y, Yoneoka D, Sugai M, Suzuki S (February 2024). "The importance of meropenem resistance, rather than imipenem resistance, in defining carbapenem-resistant Enterobacterales for public health surveillance: an analysis of national population-based surveillance". BMC Infect Dis. 24 (1) 209. doi:10.1186/s12879-024-09107-4. PMC 10870673. PMID 38360618.
Bush K (October 2018). "Past and Present Perspectives on β-Lactamases". Antimicrob Agents Chemother. 62 (10) e01076-18. doi:10.1128/AAC.01076-18. PMC 6153792. PMID 30061284.
Mora-Ochomogo M, Lohans CT (October 2021). "β-Lactam antibiotic targets and resistance mechanisms: from covalent inhibitors to substrates". RSC Med Chem. 12 (10): 1623–1639. doi:10.1039/d1md00200g. PMC 8528271. PMID 34778765.
Bush K (2010). "Bench-to-bedside review: The role of beta-lactamases in antibiotic-resistant Gram-negative infections". Crit Care. 14 (3): 224. doi:10.1186/cc8892. PMC 2911681. PMID 20594363.
Franceschini N, Segatore B, Perilli M, Vessillier S, Franchino L, Amicosante G (2002). "Meropenem stability to β-lactamase hydrolysis and comparative in vitro activity against several β-lactamase-producing Gram-negative strains". Journal of Antimicrobial Chemotherapy. 49 (2): 395–398. doi:10.1093/jac/49.2.395. PMID 11815587.
"Meropenem". ASHP Injectable Drug Information. 2021. p. 1020. doi:10.37573/9781585286850.251. ISBN 978-1-58528-658-4.
Baldwin CM, Lyseng-Williamson KA, Keam SJ (2008). "Meropenem". Drugs. 68 (6): 803–838. doi:10.2165/00003495-200868060-00006. PMID 18416587.
Wolie ZT, Roberts JA, Gilchrist M, McCarthy K, Sime FB (2024). "Current practices and challenges of outpatient parenteral antimicrobial therapy: A narrative review". The Journal of Antimicrobial Chemotherapy. 79 (9): 2083–2102. doi:10.1093/jac/dkae177. PMC 11368434. PMID 38842523.
Ortega-Balleza JL, Vázquez-Jiménez LK, Ortiz-Pérez E, Avalos-Navarro G, Paz-González AD, Lara-Ramírez EE, et al. (August 2024). "Current Strategy for Targeting Metallo-β-Lactamase with Metal-Ion-Binding Inhibitors". Molecules. 29 (16): 3944. doi:10.3390/molecules29163944. PMC 11356879. PMID 39203022.
Fawaz S, Barton S, Whitney L, Swinden J, Nabhani-Gebara S (2019). "Stability of Meropenem After Reconstitution for Administration by Prolonged Infusion". Hospital Pharmacy. 54 (3): 190–196. doi:10.1177/0018578718779009. PMC 6535930. PMID 31205331.
Palzkill T (January 2013). "Metallo-β-lactamase structure and function". Ann N Y Acad Sci. 1277 (1): 91–104. Bibcode:2013NYASA1277...91P. doi:10.1111/j.1749-6632.2012.06796.x. PMC 3970115. PMID 23163348.
Tomasello C, Leggieri A, Cavalli R, Di Perri G, D'Avolio A (April 2015). "In Vitro Stabilifighty Evaluation of Different Pharmaceutical Products Containing Meropenem". Hosp Pharm. 50 (4): 296–303. doi:10.1310/hpj5004-296. PMC 4589882. PMID 26448659.
Foy F, Luna G, Martinez J, Nizich Z, Seet J, Lie K, et al. (2019). "An investigation of the stability of meropenem in elastomeric infusion devices". Drug Des Devel Ther. 13: 2655–2665. doi:10.2147/DDDT.S212052. PMC 6682764. PMID 31447546.
Tioni MF, Llarrull LI, Poeylaut-Palena AA, Martí MA, Saggu M, Periyannan GR, et al. (November 2008). "Trapping and characterization of a reaction intermediate in carbapenem hydrolysis by B. cereus metallo-beta-lactamase". J Am Chem Soc. 130 (47): 15852–63. Bibcode:2008JAChS.13015852T. doi:10.1021/ja801169j. PMC 2645938. PMID 18980308.
Saikia S, Chetia P (September 2024). "Antibiotics: From Mechanism of Action to Resistance and Beyond". Indian J Microbiol. 64 (3): 821–845. doi:10.1007/s12088-024-01285-8. PMC 11399512. PMID 39282166.
Munita JM, Arias CA (2016). "Mechanisms of Antibiotic Resistance". Microbiology Spectrum. 4 (2) 4.2.15. doi:10.1128/microbiolspec.vmbf-0016-2015. PMC 4888801. PMID 27227291.
Bahr G, González LJ, Vila AJ (July 2021). "Metallo-β-lactamases in the Age of Multidrug Resistance: From Structure and Mechanism to Evolution, Dissemination, and Inhibitor Design". Chem Rev. 121 (13): 7957–8094. doi:10.1021/acs.chemrev.1c00138. PMC 9062786. PMID 34129337.
Celis-Llamoca K, Serna-Galvis EA, Torres-Palma RA, Nieto-Juárez JI (2022). "High-frequency ultrasound processes as alternative methods for degrading meropenem antibiotic in water". MethodsX. 9 101835. doi:10.1016/j.mex.2022.101835. PMC 9471477. PMID 36117679.
Wilamowski M, Sherrell DA, Kim Y, Lavens A, Henning RW, Lazarski K, et al. (November 2022). "Time-resolved β-lactam cleavage by L1 metallo-β-lactamase". Nat Commun. 13 (1) 7379. Bibcode:2022NatCo..13.7379W. doi:10.1038/s41467-022-35029-3. PMC 9712583. PMID 36450742.
Palermo G, Spinello A, Saha A, Magistrato A (May 2021). "Frontiers of metal-coordinating drug design". Expert Opin Drug Discov. 16 (5): 497–511. doi:10.1080/17460441.2021.1851188. PMC 8058448. PMID 33874825.
Nicolau DP (2008). "Pharmacokinetic and Pharmacodynamic Properties of Meropenem". Clinical Infectious Diseases. 47: S32–S40. doi:10.1086/590064. PMID 18713048.
Bilgrami I, Roberts JA, Wallis SC, Thomas J, Davis J, Fowler S, et al. (July 2010). "Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration". Antimicrobial Agents and Chemotherapy. 54 (7): 2974–2978. doi:10.1128/AAC.01582-09. PMC 2897321. PMID 20479205.
Steffens NA, Zimmermann ES, Nichelle SM, Brucker N (June 2021). "Meropenem use and therapeutic drug monitoring in clinical practice: a literature review". J Clin Pharm Ther. 46 (3): 610–621. doi:10.1111/jcpt.13369. PMID 33533509.
Adamiszak A, Bartkowska-Śniatkowska A, Grześkowiak E, Bienert A (2024). "Interest in antibiotic pharmacokinetic modelling in the context of optimising dosing and reducing resistance: bibliometric analysis". Anaesthesiol Intensive Ther. 56 (2): 129–140. doi:10.5114/ait.2024.141332. PMC 11284584. PMID 39166504.
Yu Z, Pang X, Wu X, Shan C, Jiang S (2018). "Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: A meta-analysis". PLOS ONE. 13 (7) e0201667. Bibcode:2018PLoSO..1301667Y. doi:10.1371/journal.pone.0201667. PMC 6066326. PMID 30059536.
Vardakas KZ, Voulgaris GL, Maliaros A, Samonis G, Falagas ME (January 2018). "Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials". The Lancet. Infectious Diseases. 18 (1): 108–120. doi:10.1016/S1473-3099(17)30615-1. PMID 29102324.
Raza A, Ngieng SC, Sime FB, Cabot PJ, Roberts JA, Popat A, et al. (February 2021). "Oral meropenem for superbugs: challenges and opportunities". Drug Discov Today. 26 (2): 551–560. doi:10.1016/j.drudis.2020.11.004. PMID 33197621. S2CID 226988098.
Monti G, Bradić N, Marzaroli M, Konkayev A, Fominskiy E, Kotani Y, et al. (2023). "Continuous vs Intermittent Meropenem Administration in Critically Ill Patients with Sepsis". JAMA. 330 (2): 141–151. doi:10.1001/jama.2023.10598. PMC 10276329. PMID 37326473.
Meaney-Delman D, Bartlett LA, Gravett MG, Jamieson DJ (April 2015). "Oral and intramuscular treatment options for early postpartum endometritis in low-resource settings: a systematic review". Obstet Gynecol. 125 (4): 789–800. doi:10.1097/AOG.0000000000000732. PMID 25751198.
Erden M, Gulcan E, Bilen A, Bilen Y, Uyanik A, Keles M (March 7, 2013). "Pancytopenýa and Sepsýs due to Meropenem: A Case Report" (PDF). Tropical Journal of Pharmaceutical Research. 12 (1). doi:10.4314/tjpr.v12i1.21. Archived (PDF) from the original on November 13, 2013. Retrieved April 20, 2013.
Margolin L (2004). "Impaired rehabilitation secondary to muscle weakness induced by meropenem". Clinical Drug Investigation. 24 (1): 61–62. doi:10.2165/00044011-200424010-00008. PMID 17516692. S2CID 44484294.
Bharti R, Gombar S, Khanna AK (2010). "Meropenem in critical care - uncovering the truths behind weaning failure". Journal of Anaesthesiology Clinical Pharmacology. 26 (1): 99–101. doi:10.4103/0970-9185.75131 (inactive August 2, 2026). S2CID 54127805. Archived from the original on February 21, 2015. Retrieved December 15, 2013.{{cite journal}}: CS1 maint: DOI inactive as of August 2026 (link)
Al-Quteimat O, Laila A (June 2020). "Valproate Interaction With Carbapenems: Review and Recommendations". Hospital Pharmacy. 55 (3): 181–187. doi:10.1177/0018578719831974. PMC 7243600. PMID 32508355.
Wiseman LR, Wagstaff AJ, Brogden RN, Bryson HM (1995). "Meropenem". Drugs. 50 (1): 73–101. doi:10.2165/00003495-199550010-00007. PMID 7588092.
Sully EK, Geller BL, Li L, Moody CM, Bailey SM, Moore AL, et al. (March 2017). "Peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) restores carbapenem susceptibility to NDM-1-positive pathogens in vitro and in vivo". The Journal of Antimicrobial Chemotherapy. 72 (3): 782–790. doi:10.1093/jac/dkw476. PMC 5890718. PMID 27999041.
Geremia N, Di Bella S, Lovecchio A, Angelini J, D'Avolio A, Luzzati R, et al. (April 3, 2025). "'Real-life' approach to applying PK/PD principles in infectious diseases clinical practice without access to prompt TDM". Expert Review of Anti-Infective Therapy. 23 (2–4): 119–134. doi:10.1080/14787210.2024.2448727. PMID 39746901.
Zusman O, Farbman L, Tredler Z, Daitch V, Lador A, Leibovici L, et al. (January 2015). "Association between hypoalbuminemia and mortality among subjects treated with ertapenem versus other carbapenems: prospective cohort study". Clinical Microbiology and Infection. 21 (1): 54–58. doi:10.1016/j.cmi.2014.08.003. PMID 25636928.
Nadeem I, Ingle T, Ur Rasool M, Mahdi N, Ul Munamm SA, Rabiei B, et al. (2023). "P114 Nebulised meropenem for prevention of bronchiectasis exacerbation". 'It's not easy being green' – Suppurative lung diseases. Vol. 78. pp. A175.1–A175. doi:10.1136/thorax-2023-BTSabstracts.266. Archived from the original on February 21, 2024. Retrieved February 21, 2024.

drugbank.com (Global: 7,932^nd place; English: 7,986^th place)

go.drugbank.com

"Meropenem trihydrate | DrugBank Online". Archived from the original on February 23, 2024. Retrieved February 23, 2024.

drugs.com (Global: 529^th place; English: 550^th place)

"Meropenem". The American Society of Health-System Pharmacists. Archived from the original on January 20, 2011. Retrieved December 8, 2017.
"Meropenem Monograph for Professionals". Archived from the original on January 20, 2011. Retrieved December 9, 2017.
"Meropenem: Package Insert". Archived from the original on February 23, 2024. Retrieved February 23, 2024.

ehealthme.com (Global: low place; English: low place)

"Meropenem side effects - from FDA reports". eHealthMe. Archived from the original on November 5, 2013. Retrieved April 20, 2013.

fda.gov (Global: 470^th place; English: 329^th place)

fda.gov

"Merrem® IV (meropenem for injection)". Pediatric Postmarketing Pharmacovigilance Review. Food and Drug Administration. November 17, 2017. Archived from the original on March 5, 2021. Retrieved February 23, 2024.
"FDA approves new antibacterial drug". U.S. Food and Drug Administration (FDA) (Press release). March 24, 2020. Archived from the original on April 23, 2019. Retrieved March 5, 2022. This article incorporates text from this source, which is in the public domain.

accessdata.fda.gov

"Approval package for meropenem for injection" (PDF). Archived (PDF) from the original on April 12, 2021. Retrieved February 23, 2024.
"NDA 50-706/S-022 MERREM I.V." (PDF). Archived (PDF) from the original on February 21, 2024. Retrieved February 21, 2024.

hdl.handle.net (Global: 66^th place; English: 34^th place)

Organization WH (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
Organization WH (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
Critically important antimicrobials for human medicine (6th revision ed.). Geneva: World Health Organization. 2019. hdl:10665/312266. ISBN 978-92-4-151552-8.

hefnypharmagroup.info (Global: low place; English: low place)

"Hefny Pharma Group". hefnypharmagroup.info. Archived from the original on May 23, 2018. Retrieved May 22, 2018.

hpfb-dgpsa.ca (Global: low place; English: low place)

dhpp.hpfb-dgpsa.ca

"Regulatory Decision Summary for Meropenem for Injection USP and Sodium Chloride Injection USP". Drug and Health Products Portal. January 4, 2024. Archived from the original on September 7, 2024. Retrieved April 2, 2024.

joacp.org (Global: low place; English: low place)

Bharti R, Gombar S, Khanna AK (2010). "Meropenem in critical care - uncovering the truths behind weaning failure". Journal of Anaesthesiology Clinical Pharmacology. 26 (1): 99–101. doi:10.4103/0970-9185.75131 (inactive August 2, 2026). S2CID 54127805. Archived from the original on February 21, 2015. Retrieved December 15, 2013.{{cite journal}}: CS1 maint: DOI inactive as of August 2026 (link)

medicines.org.uk (Global: 4,892^nd place; English: 3,451^st place)

"Meropenem 1g powder for solution for injection/Infusion - Summary of Product Characteristics (SMPC) - (Emc)". Archived from the original on February 22, 2024. Retrieved February 22, 2024.

medlineplus.gov (Global: 1,521^st place; English: 1,017^th place)

"Meropenem". MedlinePlus.gov. September 16, 2016. Archived from the original on March 19, 2023. Retrieved March 19, 2023.

newatlas.com (Global: 5,974^th place; English: 3,758^th place)

"New molecule knocks out superbugs' immunity to antibiotics". newatlas.com. January 20, 2017. Archived from the original on January 22, 2017. Retrieved January 25, 2017.

nih.gov (Global: 5^th place; English: 5^th place)

pubmed.ncbi.nlm.nih.gov

Mohr Iii JF (2008). "Update on the Efficacy and Tolerability of Meropenem in the Treatment of Serious Bacterial Infections". Clinical Infectious Diseases. 47: S41–S51. doi:10.1086/590065. PMID 18713049.
Ikenoue C, Matsui M, Inamine Y, Yoneoka D, Sugai M, Suzuki S (February 2024). "The importance of meropenem resistance, rather than imipenem resistance, in defining carbapenem-resistant Enterobacterales for public health surveillance: an analysis of national population-based surveillance". BMC Infect Dis. 24 (1) 209. doi:10.1186/s12879-024-09107-4. PMC 10870673. PMID 38360618.
Bush K (October 2018). "Past and Present Perspectives on β-Lactamases". Antimicrob Agents Chemother. 62 (10) e01076-18. doi:10.1128/AAC.01076-18. PMC 6153792. PMID 30061284.
Mora-Ochomogo M, Lohans CT (October 2021). "β-Lactam antibiotic targets and resistance mechanisms: from covalent inhibitors to substrates". RSC Med Chem. 12 (10): 1623–1639. doi:10.1039/d1md00200g. PMC 8528271. PMID 34778765.
Bush K (2010). "Bench-to-bedside review: The role of beta-lactamases in antibiotic-resistant Gram-negative infections". Crit Care. 14 (3): 224. doi:10.1186/cc8892. PMC 2911681. PMID 20594363.
Franceschini N, Segatore B, Perilli M, Vessillier S, Franchino L, Amicosante G (2002). "Meropenem stability to β-lactamase hydrolysis and comparative in vitro activity against several β-lactamase-producing Gram-negative strains". Journal of Antimicrobial Chemotherapy. 49 (2): 395–398. doi:10.1093/jac/49.2.395. PMID 11815587.
Baldwin CM, Lyseng-Williamson KA, Keam SJ (2008). "Meropenem". Drugs. 68 (6): 803–838. doi:10.2165/00003495-200868060-00006. PMID 18416587.
Wolie ZT, Roberts JA, Gilchrist M, McCarthy K, Sime FB (2024). "Current practices and challenges of outpatient parenteral antimicrobial therapy: A narrative review". The Journal of Antimicrobial Chemotherapy. 79 (9): 2083–2102. doi:10.1093/jac/dkae177. PMC 11368434. PMID 38842523.
Ortega-Balleza JL, Vázquez-Jiménez LK, Ortiz-Pérez E, Avalos-Navarro G, Paz-González AD, Lara-Ramírez EE, et al. (August 2024). "Current Strategy for Targeting Metallo-β-Lactamase with Metal-Ion-Binding Inhibitors". Molecules. 29 (16): 3944. doi:10.3390/molecules29163944. PMC 11356879. PMID 39203022.
Fawaz S, Barton S, Whitney L, Swinden J, Nabhani-Gebara S (2019). "Stability of Meropenem After Reconstitution for Administration by Prolonged Infusion". Hospital Pharmacy. 54 (3): 190–196. doi:10.1177/0018578718779009. PMC 6535930. PMID 31205331.
Palzkill T (January 2013). "Metallo-β-lactamase structure and function". Ann N Y Acad Sci. 1277 (1): 91–104. Bibcode:2013NYASA1277...91P. doi:10.1111/j.1749-6632.2012.06796.x. PMC 3970115. PMID 23163348.
Tomasello C, Leggieri A, Cavalli R, Di Perri G, D'Avolio A (April 2015). "In Vitro Stabilifighty Evaluation of Different Pharmaceutical Products Containing Meropenem". Hosp Pharm. 50 (4): 296–303. doi:10.1310/hpj5004-296. PMC 4589882. PMID 26448659.
Foy F, Luna G, Martinez J, Nizich Z, Seet J, Lie K, et al. (2019). "An investigation of the stability of meropenem in elastomeric infusion devices". Drug Des Devel Ther. 13: 2655–2665. doi:10.2147/DDDT.S212052. PMC 6682764. PMID 31447546.
Tioni MF, Llarrull LI, Poeylaut-Palena AA, Martí MA, Saggu M, Periyannan GR, et al. (November 2008). "Trapping and characterization of a reaction intermediate in carbapenem hydrolysis by B. cereus metallo-beta-lactamase". J Am Chem Soc. 130 (47): 15852–63. Bibcode:2008JAChS.13015852T. doi:10.1021/ja801169j. PMC 2645938. PMID 18980308.
Saikia S, Chetia P (September 2024). "Antibiotics: From Mechanism of Action to Resistance and Beyond". Indian J Microbiol. 64 (3): 821–845. doi:10.1007/s12088-024-01285-8. PMC 11399512. PMID 39282166.
Munita JM, Arias CA (2016). "Mechanisms of Antibiotic Resistance". Microbiology Spectrum. 4 (2) 4.2.15. doi:10.1128/microbiolspec.vmbf-0016-2015. PMC 4888801. PMID 27227291.
Bahr G, González LJ, Vila AJ (July 2021). "Metallo-β-lactamases in the Age of Multidrug Resistance: From Structure and Mechanism to Evolution, Dissemination, and Inhibitor Design". Chem Rev. 121 (13): 7957–8094. doi:10.1021/acs.chemrev.1c00138. PMC 9062786. PMID 34129337.
Celis-Llamoca K, Serna-Galvis EA, Torres-Palma RA, Nieto-Juárez JI (2022). "High-frequency ultrasound processes as alternative methods for degrading meropenem antibiotic in water". MethodsX. 9 101835. doi:10.1016/j.mex.2022.101835. PMC 9471477. PMID 36117679.
Wilamowski M, Sherrell DA, Kim Y, Lavens A, Henning RW, Lazarski K, et al. (November 2022). "Time-resolved β-lactam cleavage by L1 metallo-β-lactamase". Nat Commun. 13 (1) 7379. Bibcode:2022NatCo..13.7379W. doi:10.1038/s41467-022-35029-3. PMC 9712583. PMID 36450742.
Palermo G, Spinello A, Saha A, Magistrato A (May 2021). "Frontiers of metal-coordinating drug design". Expert Opin Drug Discov. 16 (5): 497–511. doi:10.1080/17460441.2021.1851188. PMC 8058448. PMID 33874825.
Nicolau DP (2008). "Pharmacokinetic and Pharmacodynamic Properties of Meropenem". Clinical Infectious Diseases. 47: S32–S40. doi:10.1086/590064. PMID 18713048.
Bilgrami I, Roberts JA, Wallis SC, Thomas J, Davis J, Fowler S, et al. (July 2010). "Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration". Antimicrobial Agents and Chemotherapy. 54 (7): 2974–2978. doi:10.1128/AAC.01582-09. PMC 2897321. PMID 20479205.
Steffens NA, Zimmermann ES, Nichelle SM, Brucker N (June 2021). "Meropenem use and therapeutic drug monitoring in clinical practice: a literature review". J Clin Pharm Ther. 46 (3): 610–621. doi:10.1111/jcpt.13369. PMID 33533509.
Adamiszak A, Bartkowska-Śniatkowska A, Grześkowiak E, Bienert A (2024). "Interest in antibiotic pharmacokinetic modelling in the context of optimising dosing and reducing resistance: bibliometric analysis". Anaesthesiol Intensive Ther. 56 (2): 129–140. doi:10.5114/ait.2024.141332. PMC 11284584. PMID 39166504.
Yu Z, Pang X, Wu X, Shan C, Jiang S (2018). "Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: A meta-analysis". PLOS ONE. 13 (7) e0201667. Bibcode:2018PLoSO..1301667Y. doi:10.1371/journal.pone.0201667. PMC 6066326. PMID 30059536.
Vardakas KZ, Voulgaris GL, Maliaros A, Samonis G, Falagas ME (January 2018). "Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials". The Lancet. Infectious Diseases. 18 (1): 108–120. doi:10.1016/S1473-3099(17)30615-1. PMID 29102324.
Raza A, Ngieng SC, Sime FB, Cabot PJ, Roberts JA, Popat A, et al. (February 2021). "Oral meropenem for superbugs: challenges and opportunities". Drug Discov Today. 26 (2): 551–560. doi:10.1016/j.drudis.2020.11.004. PMID 33197621. S2CID 226988098.
Monti G, Bradić N, Marzaroli M, Konkayev A, Fominskiy E, Kotani Y, et al. (2023). "Continuous vs Intermittent Meropenem Administration in Critically Ill Patients with Sepsis". JAMA. 330 (2): 141–151. doi:10.1001/jama.2023.10598. PMC 10276329. PMID 37326473.
"Meropenem". Drugs and Lactation Database (LactMed) [Internet]. National Institute of Child Health and Human Development. 2006. PMID 30000076.
Tallarigo C, Comunale L, Baldassarre R, Poletti G (September 1995). "[Multicenter comparative study of meropenem vs. imipenem in the intramuscular treatment of hospital infections of the urinary tract]". Minerva Urol Nefrol (in Italian). 47 (3): 147–56. PMID 8815553.
Meaney-Delman D, Bartlett LA, Gravett MG, Jamieson DJ (April 2015). "Oral and intramuscular treatment options for early postpartum endometritis in low-resource settings: a systematic review". Obstet Gynecol. 125 (4): 789–800. doi:10.1097/AOG.0000000000000732. PMID 25751198.
Lizasoaín M, Noriega AR (September 1997). "[Tolerance and safety of carbapenems: the use of meropenem]". Enferm Infecc Microbiol Clin (in European Spanish). 15 (Suppl 1): 73–7. PMID 9410074.
Margolin L (2004). "Impaired rehabilitation secondary to muscle weakness induced by meropenem". Clinical Drug Investigation. 24 (1): 61–62. doi:10.2165/00044011-200424010-00008. PMID 17516692. S2CID 44484294.
Al-Quteimat O, Laila A (June 2020). "Valproate Interaction With Carbapenems: Review and Recommendations". Hospital Pharmacy. 55 (3): 181–187. doi:10.1177/0018578719831974. PMC 7243600. PMID 32508355.
Wiseman LR, Wagstaff AJ, Brogden RN, Bryson HM (1995). "Meropenem". Drugs. 50 (1): 73–101. doi:10.2165/00003495-199550010-00007. PMID 7588092.
Sully EK, Geller BL, Li L, Moody CM, Bailey SM, Moore AL, et al. (March 2017). "Peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) restores carbapenem susceptibility to NDM-1-positive pathogens in vitro and in vivo". The Journal of Antimicrobial Chemotherapy. 72 (3): 782–790. doi:10.1093/jac/dkw476. PMC 5890718. PMID 27999041.
Geremia N, Di Bella S, Lovecchio A, Angelini J, D'Avolio A, Luzzati R, et al. (April 3, 2025). "'Real-life' approach to applying PK/PD principles in infectious diseases clinical practice without access to prompt TDM". Expert Review of Anti-Infective Therapy. 23 (2–4): 119–134. doi:10.1080/14787210.2024.2448727. PMID 39746901.
Zusman O, Farbman L, Tredler Z, Daitch V, Lador A, Leibovici L, et al. (January 2015). "Association between hypoalbuminemia and mortality among subjects treated with ertapenem versus other carbapenems: prospective cohort study". Clinical Microbiology and Infection. 21 (1): 54–58. doi:10.1016/j.cmi.2014.08.003. PMID 25636928.

ncbi.nlm.nih.gov

Ikenoue C, Matsui M, Inamine Y, Yoneoka D, Sugai M, Suzuki S (February 2024). "The importance of meropenem resistance, rather than imipenem resistance, in defining carbapenem-resistant Enterobacterales for public health surveillance: an analysis of national population-based surveillance". BMC Infect Dis. 24 (1) 209. doi:10.1186/s12879-024-09107-4. PMC 10870673. PMID 38360618.
Bush K (October 2018). "Past and Present Perspectives on β-Lactamases". Antimicrob Agents Chemother. 62 (10) e01076-18. doi:10.1128/AAC.01076-18. PMC 6153792. PMID 30061284.
Mora-Ochomogo M, Lohans CT (October 2021). "β-Lactam antibiotic targets and resistance mechanisms: from covalent inhibitors to substrates". RSC Med Chem. 12 (10): 1623–1639. doi:10.1039/d1md00200g. PMC 8528271. PMID 34778765.
Bush K (2010). "Bench-to-bedside review: The role of beta-lactamases in antibiotic-resistant Gram-negative infections". Crit Care. 14 (3): 224. doi:10.1186/cc8892. PMC 2911681. PMID 20594363.
Wolie ZT, Roberts JA, Gilchrist M, McCarthy K, Sime FB (2024). "Current practices and challenges of outpatient parenteral antimicrobial therapy: A narrative review". The Journal of Antimicrobial Chemotherapy. 79 (9): 2083–2102. doi:10.1093/jac/dkae177. PMC 11368434. PMID 38842523.
Ortega-Balleza JL, Vázquez-Jiménez LK, Ortiz-Pérez E, Avalos-Navarro G, Paz-González AD, Lara-Ramírez EE, et al. (August 2024). "Current Strategy for Targeting Metallo-β-Lactamase with Metal-Ion-Binding Inhibitors". Molecules. 29 (16): 3944. doi:10.3390/molecules29163944. PMC 11356879. PMID 39203022.
Fawaz S, Barton S, Whitney L, Swinden J, Nabhani-Gebara S (2019). "Stability of Meropenem After Reconstitution for Administration by Prolonged Infusion". Hospital Pharmacy. 54 (3): 190–196. doi:10.1177/0018578718779009. PMC 6535930. PMID 31205331.
Palzkill T (January 2013). "Metallo-β-lactamase structure and function". Ann N Y Acad Sci. 1277 (1): 91–104. Bibcode:2013NYASA1277...91P. doi:10.1111/j.1749-6632.2012.06796.x. PMC 3970115. PMID 23163348.
Tomasello C, Leggieri A, Cavalli R, Di Perri G, D'Avolio A (April 2015). "In Vitro Stabilifighty Evaluation of Different Pharmaceutical Products Containing Meropenem". Hosp Pharm. 50 (4): 296–303. doi:10.1310/hpj5004-296. PMC 4589882. PMID 26448659.
Foy F, Luna G, Martinez J, Nizich Z, Seet J, Lie K, et al. (2019). "An investigation of the stability of meropenem in elastomeric infusion devices". Drug Des Devel Ther. 13: 2655–2665. doi:10.2147/DDDT.S212052. PMC 6682764. PMID 31447546.
Tioni MF, Llarrull LI, Poeylaut-Palena AA, Martí MA, Saggu M, Periyannan GR, et al. (November 2008). "Trapping and characterization of a reaction intermediate in carbapenem hydrolysis by B. cereus metallo-beta-lactamase". J Am Chem Soc. 130 (47): 15852–63. Bibcode:2008JAChS.13015852T. doi:10.1021/ja801169j. PMC 2645938. PMID 18980308.
Saikia S, Chetia P (September 2024). "Antibiotics: From Mechanism of Action to Resistance and Beyond". Indian J Microbiol. 64 (3): 821–845. doi:10.1007/s12088-024-01285-8. PMC 11399512. PMID 39282166.
Munita JM, Arias CA (2016). "Mechanisms of Antibiotic Resistance". Microbiology Spectrum. 4 (2) 4.2.15. doi:10.1128/microbiolspec.vmbf-0016-2015. PMC 4888801. PMID 27227291.
Bahr G, González LJ, Vila AJ (July 2021). "Metallo-β-lactamases in the Age of Multidrug Resistance: From Structure and Mechanism to Evolution, Dissemination, and Inhibitor Design". Chem Rev. 121 (13): 7957–8094. doi:10.1021/acs.chemrev.1c00138. PMC 9062786. PMID 34129337.
Celis-Llamoca K, Serna-Galvis EA, Torres-Palma RA, Nieto-Juárez JI (2022). "High-frequency ultrasound processes as alternative methods for degrading meropenem antibiotic in water". MethodsX. 9 101835. doi:10.1016/j.mex.2022.101835. PMC 9471477. PMID 36117679.
Wilamowski M, Sherrell DA, Kim Y, Lavens A, Henning RW, Lazarski K, et al. (November 2022). "Time-resolved β-lactam cleavage by L1 metallo-β-lactamase". Nat Commun. 13 (1) 7379. Bibcode:2022NatCo..13.7379W. doi:10.1038/s41467-022-35029-3. PMC 9712583. PMID 36450742.
Palermo G, Spinello A, Saha A, Magistrato A (May 2021). "Frontiers of metal-coordinating drug design". Expert Opin Drug Discov. 16 (5): 497–511. doi:10.1080/17460441.2021.1851188. PMC 8058448. PMID 33874825.
Bilgrami I, Roberts JA, Wallis SC, Thomas J, Davis J, Fowler S, et al. (July 2010). "Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration". Antimicrobial Agents and Chemotherapy. 54 (7): 2974–2978. doi:10.1128/AAC.01582-09. PMC 2897321. PMID 20479205.
Adamiszak A, Bartkowska-Śniatkowska A, Grześkowiak E, Bienert A (2024). "Interest in antibiotic pharmacokinetic modelling in the context of optimising dosing and reducing resistance: bibliometric analysis". Anaesthesiol Intensive Ther. 56 (2): 129–140. doi:10.5114/ait.2024.141332. PMC 11284584. PMID 39166504.
Yu Z, Pang X, Wu X, Shan C, Jiang S (2018). "Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: A meta-analysis". PLOS ONE. 13 (7) e0201667. Bibcode:2018PLoSO..1301667Y. doi:10.1371/journal.pone.0201667. PMC 6066326. PMID 30059536.
Monti G, Bradić N, Marzaroli M, Konkayev A, Fominskiy E, Kotani Y, et al. (2023). "Continuous vs Intermittent Meropenem Administration in Critically Ill Patients with Sepsis". JAMA. 330 (2): 141–151. doi:10.1001/jama.2023.10598. PMC 10276329. PMID 37326473.
Al-Quteimat O, Laila A (June 2020). "Valproate Interaction With Carbapenems: Review and Recommendations". Hospital Pharmacy. 55 (3): 181–187. doi:10.1177/0018578719831974. PMC 7243600. PMID 32508355.
Sully EK, Geller BL, Li L, Moody CM, Bailey SM, Moore AL, et al. (March 2017). "Peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) restores carbapenem susceptibility to NDM-1-positive pathogens in vitro and in vivo". The Journal of Antimicrobial Chemotherapy. 72 (3): 782–790. doi:10.1093/jac/dkw476. PMC 5890718. PMID 27999041.

dailymed.nlm.nih.gov

"DailyMed - MEROPENEM injection, powder, for solution". Archived from the original on June 20, 2024. Retrieved November 2, 2024.

pubchem.ncbi.nlm.nih.gov

"Meropenem". Archived from the original on February 23, 2024. Retrieved February 23, 2024.

semanticscholar.org (Global: 15^th place; English: 8^th place)

api.semanticscholar.org

Raza A, Ngieng SC, Sime FB, Cabot PJ, Roberts JA, Popat A, et al. (February 2021). "Oral meropenem for superbugs: challenges and opportunities". Drug Discov Today. 26 (2): 551–560. doi:10.1016/j.drudis.2020.11.004. PMID 33197621. S2CID 226988098.
Margolin L (2004). "Impaired rehabilitation secondary to muscle weakness induced by meropenem". Clinical Drug Investigation. 24 (1): 61–62. doi:10.2165/00044011-200424010-00008. PMID 17516692. S2CID 44484294.
Bharti R, Gombar S, Khanna AK (2010). "Meropenem in critical care - uncovering the truths behind weaning failure". Journal of Anaesthesiology Clinical Pharmacology. 26 (1): 99–101. doi:10.4103/0970-9185.75131 (inactive August 2, 2026). S2CID 54127805. Archived from the original on February 21, 2015. Retrieved December 15, 2013.{{cite journal}}: CS1 maint: DOI inactive as of August 2026 (link)

stanford.edu (Global: 194^th place; English: 182^nd place)

med.stanford.edu

"Medication Administration: Extended-Infusion Meropenem (Merrem) Protocol" (PDF). Pharmacy Department Policies and Procedures. Stanford Hospital and Clinics. Archived (PDF) from the original on June 3, 2024. Retrieved October 20, 2024.

tga.gov.au (Global: 4,353^rd place; English: 2,806^th place)

"MEROPENEM-AFT (AFT Pharmaceuticals Pty Ltd)". Archived from the original on September 15, 2024. Retrieved September 15, 2024.

tjpr.org (Global: low place; English: low place)

Erden M, Gulcan E, Bilen A, Bilen Y, Uyanik A, Keles M (March 7, 2013). "Pancytopenýa and Sepsýs due to Meropenem: A Case Report" (PDF). Tropical Journal of Pharmaceutical Research. 12 (1). doi:10.4314/tjpr.v12i1.21. Archived (PDF) from the original on November 13, 2013. Retrieved April 20, 2013.

web.archive.org (Global: 1^st place; English: 1^st place)

"MEROPENEM-AFT (AFT Pharmaceuticals Pty Ltd)". Archived from the original on September 15, 2024. Retrieved September 15, 2024.
"Regulatory Decision Summary for Meropenem for Injection USP and Sodium Chloride Injection USP". Drug and Health Products Portal. January 4, 2024. Archived from the original on September 7, 2024. Retrieved April 2, 2024.
"Meropenem". The American Society of Health-System Pharmacists. Archived from the original on January 20, 2011. Retrieved December 8, 2017.
Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 497. ISBN 978-3-527-60749-5. Archived from the original on February 27, 2024. Retrieved September 20, 2020.
"Meropenem". MedlinePlus.gov. September 16, 2016. Archived from the original on March 19, 2023. Retrieved March 19, 2023.
"Merrem® IV (meropenem for injection)". Pediatric Postmarketing Pharmacovigilance Review. Food and Drug Administration. November 17, 2017. Archived from the original on March 5, 2021. Retrieved February 23, 2024.
"Approval package for meropenem for injection" (PDF). Archived (PDF) from the original on April 12, 2021. Retrieved February 23, 2024.
"Meropenem Monograph for Professionals". Archived from the original on January 20, 2011. Retrieved December 9, 2017.
"FDA approves new antibacterial drug". U.S. Food and Drug Administration (FDA) (Press release). March 24, 2020. Archived from the original on April 23, 2019. Retrieved March 5, 2022. This article incorporates text from this source, which is in the public domain.
"DailyMed - MEROPENEM injection, powder, for solution". Archived from the original on June 20, 2024. Retrieved November 2, 2024.
"NDA 50-706/S-022 MERREM I.V." (PDF). Archived (PDF) from the original on February 21, 2024. Retrieved February 21, 2024.
"Meropenem trihydrate | DrugBank Online". Archived from the original on February 23, 2024. Retrieved February 23, 2024.
"Meropenem". Archived from the original on February 23, 2024. Retrieved February 23, 2024.
"Meropenem 1g powder for solution for injection/Infusion - Summary of Product Characteristics (SMPC) - (Emc)". Archived from the original on February 22, 2024. Retrieved February 22, 2024.
"Meropenem: Package Insert". Archived from the original on February 23, 2024. Retrieved February 23, 2024.
"Medication Administration: Extended-Infusion Meropenem (Merrem) Protocol" (PDF). Pharmacy Department Policies and Procedures. Stanford Hospital and Clinics. Archived (PDF) from the original on June 3, 2024. Retrieved October 20, 2024.
Erden M, Gulcan E, Bilen A, Bilen Y, Uyanik A, Keles M (March 7, 2013). "Pancytopenýa and Sepsýs due to Meropenem: A Case Report" (PDF). Tropical Journal of Pharmaceutical Research. 12 (1). doi:10.4314/tjpr.v12i1.21. Archived (PDF) from the original on November 13, 2013. Retrieved April 20, 2013.
"Meropenem side effects - from FDA reports". eHealthMe. Archived from the original on November 5, 2013. Retrieved April 20, 2013.
Bharti R, Gombar S, Khanna AK (2010). "Meropenem in critical care - uncovering the truths behind weaning failure". Journal of Anaesthesiology Clinical Pharmacology. 26 (1): 99–101. doi:10.4103/0970-9185.75131 (inactive August 2, 2026). S2CID 54127805. Archived from the original on February 21, 2015. Retrieved December 15, 2013.{{cite journal}}: CS1 maint: DOI inactive as of August 2026 (link)
"New molecule knocks out superbugs' immunity to antibiotics". newatlas.com. January 20, 2017. Archived from the original on January 22, 2017. Retrieved January 25, 2017.
Nadeem I, Ingle T, Ur Rasool M, Mahdi N, Ul Munamm SA, Rabiei B, et al. (2023). "P114 Nebulised meropenem for prevention of bronchiectasis exacerbation". 'It's not easy being green' – Suppurative lung diseases. Vol. 78. pp. A175.1–A175. doi:10.1136/thorax-2023-BTSabstracts.266. Archived from the original on February 21, 2024. Retrieved February 21, 2024.
"Меропенем (Meropenemum)". compendium.com.ua (in Ukrainian). Compendium. Archived from the original on May 20, 2022. Retrieved May 21, 2022.
"Hefny Pharma Group". hefnypharmagroup.info. Archived from the original on May 23, 2018. Retrieved May 22, 2018.

Meropenem (English Wikipedia)

adsabs.harvard.edu (Global: 14th place; English: 9th place)

ui.adsabs.harvard.edu

bmj.com (Global: 1,341st place; English: 1,425th place)

thorax.bmj.com

books.google.com (Global: 3rd place; English: 3rd place)

compendium.com.ua (Global: low place; English: low place)

doi.org (Global: 2nd place; English: 2nd place)

drugbank.com (Global: 7,932nd place; English: 7,986th place)

go.drugbank.com

drugs.com (Global: 529th place; English: 550th place)

ehealthme.com (Global: low place; English: low place)

fda.gov (Global: 470th place; English: 329th place)

fda.gov

accessdata.fda.gov

hdl.handle.net (Global: 66th place; English: 34th place)

hefnypharmagroup.info (Global: low place; English: low place)

hpfb-dgpsa.ca (Global: low place; English: low place)

dhpp.hpfb-dgpsa.ca

joacp.org (Global: low place; English: low place)

medicines.org.uk (Global: 4,892nd place; English: 3,451st place)

medlineplus.gov (Global: 1,521st place; English: 1,017th place)

newatlas.com (Global: 5,974th place; English: 3,758th place)

nih.gov (Global: 5th place; English: 5th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

pubchem.ncbi.nlm.nih.gov

semanticscholar.org (Global: 15th place; English: 8th place)

api.semanticscholar.org

stanford.edu (Global: 194th place; English: 182nd place)

med.stanford.edu

tga.gov.au (Global: 4,353rd place; English: 2,806th place)

tjpr.org (Global: low place; English: low place)

web.archive.org (Global: 1st place; English: 1st place)

adsabs.harvard.edu (Global: 14^th place; English: 9^th place)

bmj.com (Global: 1,341^st place; English: 1,425^th place)

books.google.com (Global: 3^rd place; English: 3^rd place)

doi.org (Global: 2^nd place; English: 2^nd place)

drugbank.com (Global: 7,932^nd place; English: 7,986^th place)

drugs.com (Global: 529^th place; English: 550^th place)

fda.gov (Global: 470^th place; English: 329^th place)

hdl.handle.net (Global: 66^th place; English: 34^th place)

medicines.org.uk (Global: 4,892^nd place; English: 3,451^st place)

medlineplus.gov (Global: 1,521^st place; English: 1,017^th place)

newatlas.com (Global: 5,974^th place; English: 3,758^th place)

nih.gov (Global: 5^th place; English: 5^th place)

semanticscholar.org (Global: 15^th place; English: 8^th place)

stanford.edu (Global: 194^th place; English: 182^nd place)

tga.gov.au (Global: 4,353^rd place; English: 2,806^th place)

web.archive.org (Global: 1^st place; English: 1^st place)